# US 2026/0218230 A1 · Helper gene control

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218230 A1
- Document ID: US20260218230A1
- Status: Published application
- Kind: A1
- Application number: 19/143,609
- Filed: 2023-12-26
- Published: 2026-07-30
- Earliest claimed: 2022-12-27
- Assignees: Synplogen Co., Ltd.
- Applicants: Synplogen Co., Ltd.
- Inventors: Yuya NISHIMURA; Shunsuke SAITO
- Web page: https://patentgrep.com/patent/US20260218230A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N 2830/003: tet inducible
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides control of expression of a Rep gene by control of expression of a helper gene. In one aspect, the present disclosure provides a method for controlling the expression of a Rep gene, including a step of controlling the expression of a helper gene. In one embodiment, the helper gene includes a gene selected from adenovirus E1B, E2, E4 and VA. In one embodiment, the helper gene includes an adenovirus E1B gene. In one embodiment, the helper gene includes two or more helper genes related to the production of an adeno-associated virus (AAV)-derived construct, and optionally, the helper genes can be selected from E1A, E1B, E2, E4, and VA. In one embodiment, the helper gene includes a helper gene selected from E1A and E1B and a helper gene selected from E2, E4 and VA.

## Claims

### Claim 1

A method for controlling expression of a Rep gene, comprising a step of controlling expression of a helper gene selected from E1B, E2, E4 and VA.

### Claim 2

A method for controlling expression of a Rep gene, comprising a step of controlling expression of an E1B helper gene.

### Claim 3

A method for controlling expression of a Rep gene, comprising a step of controlling expression of two or more helper genes related to production of an adeno-associated virus (AAV)-derived construct.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the helper gene includes a helper gene selected from E1A, E1B, E2, E4 and VA.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the helper gene includes a helper gene selected from E1A and E1B and a helper gene selected from E2, E4 and VA.

### Claim 6 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein a decrease in expression of the helper gene results in a decrease in expression of the Rep gene.

### Claim 7 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the step of controlling expression of the helper gene uses an expression control system having at least one of the following functions of controlling activity of a promoter operably linked to the helper gene, degrading nucleic acids transcribed from the helper gene, making the helper gene transcriptionally inactive, and degrading a protein encoded by the helper gene.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the expression control system is activated by addition or removal of a drug.

### Claim 9 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the expression control system includes a stimuli-responsive promoter operably linked to the helper gene, a Cre protein-responsive nucleic acid region that enables removal or inversion of at least a part of a nucleic acid region of the helper gene or a promoter operably linked thereto, a CRISPR-Cas9 system, or an shRNA for a nucleic acid transcribed from the helper gene.

### Claim 10 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, further comprising a step of triggering an expression control system for the Rep other than the helper gene.

### Claim 11 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein expression of the Rep gene is controlled in a cell containing the helper gene and the Rep gene.

### Claim 12 (depends on 1, 2, 3)

The method according to any one of claim 1 to 3, wherein expression of the Rep gene is controlled in a producer cell containing the helper gene and the Rep gene that produces an AAV-derived construct.

### Claim 13 (depends on 12)

The method according to claim 12, wherein production of the AAV-derived construct is controlled by controlling expression of the helper gene.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the producer cell contains an inverted terminal repeat (ITR), a gene of interest (GOI), and a Cap gene.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the producer cell contains the helper gene, ITR, GOI, Cap gene, and Rep gene in a chromosome.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the producer cell contains the helper gene, ITR, GOI, Cap gene, and Rep gene at one locus on a chromosome.

### Claim 17

A combination for controlling expression of a Rep gene, comprising: a nucleic acid containing a Rep gene;
a nucleic acid containing a helper gene selected from E1B, E2, E4 and VA; and
a control system for the helper gene.

### Claim 18

A combination for controlling expression of a Rep gene, comprising: a nucleic acid containing a Rep gene;
a nucleic acid containing two or more helper genes required for production of an adeno-associated virus (AAV)-derived construct; and
a control system for the helper gene.

### Claim 19 (depends on 18)

The combination according to claim 18, wherein the helper gene includes a helper gene selected from E1A, E1B, E2, E4 and VA.

### Claim 20 (depends on 18)

The combination according to claim 18, wherein the helper gene includes a helper gene selected from E1A and E1B and a helper gene selected from E2, E4 and VA.

### Claim 21 (depends on 17, 18)

The combination according to claim 17 or 18, wherein the nucleic acid containing the Rep gene and the nucleic acid containing the helper gene form separate molecules or separate double-stranded complexes.

### Claim 22 (depends on 17, 18)

The combination according to claim 17 or 18, wherein the nucleic acid containing the Rep gene and the nucleic acid containing the helper gene form the same molecule or the same double-stranded complex.

### Claim 23 (depends on 17, 18)

The combination according to claim 17 or 18, wherein the control system includes a combination of a drug and the drug-responsive promoter operably linked to the helper gene, a combination of a Cre protein and the Cre protein-responsive nucleic acid region that enables removal of a poly A region linked to the helper gene, or an shRNA for a nucleic acid transcribed from the helper gene.

### Claim 24 (depends on 17, 18)

The combination according to claim 17 or 18, wherein the nucleic acid containing the Rep gene and/or the nucleic acid containing the helper gene is a plasmid.

### Claim 25 (depends on 17, 18)

The combination according to claim 17 or 18, wherein the nucleic acid containing the Rep gene and/or the nucleic acid containing the helper gene forms a complex with a cationic substance.

### Claim 26 (depends on 17, 18)

The combination according to claim 17 or 18, comprising a cell that contains a nucleic acid containing the Rep gene and a nucleic acid containing the helper gene.

### Claim 27 (depends on 26)

The combination according to claim 26, wherein the cell is a producer cell that produces an AAV-derived construct.

### Claim 28 (depends on 27)

The combination according to claim 27, wherein the producer cell contains an inverted terminal repeat (ITR), a gene of interest (GOI), and a Cap gene.

### Claim 29 (depends on 28)

The combination according to claim 28, wherein the producer cell contains the helper gene, ITR, GOI, Cap gene, and Rep gene in a chromosome.

### Claim 30 (depends on 28)

The combination according to claim 28, wherein the producer cell contains the helper gene, ITR, GOI, Cap gene, and Rep gene at one locus on a chromosome.

### Claim 31 (depends on 17, 18)

A method of producing an adeno-associated virus (AAV)-derived construct using the combination according to claim 17 or 18, the method comprising:
a step of preparing a producer cell that contains a nucleic acid containing the Rep gene and a nucleic acid containing the helper gene; and
a step of controlling expression of the Rep gene using a control system for the helper gene.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the producer cell contains the helper gene and the Rep gene in a chromosome.

### Claim 33 (depends on 31)

An AAV-derived construct produced by the method according to claim 31.
